• Vaccine Name: Herpes simplex virus type 1 DNA vaccine encoding GD
• Target Pathogen: Herpes simplex virus type 1 and 2
• Target Disease: Herpes
• Vaccine Ontology ID: VO_0011421
• Type: DNA vaccine
• Status: Research
• Antigen: Herpes simplex virus type1 glycoprotein D
• US5 gene engineering:
  • Type: DNA vaccine construction
  • Description: Plasmid DNA encoding HSV-1 glycoprotein D1 (gD1) was constructed by insertion of the gD1 gene into pcDNA3 (Jamali et al., 2009).
  • Detailed Gene Information: Click Here.
• DNA vaccine plasmid: pcDNA3 DNA vaccine plasmid
  • DNA vaccine plasmid name: pcDNA3 DNA vaccine plasmid
  • DNA vaccine plasmid VO ID: VO_0000132
• Immunization Route: Intradermal injection (i.d.)

Mouse Response

• Host Strain: BALB/c
• Vaccination Protocol: BALB/c mice were immunized three times intra-dermally with 50 µg of pcDNA3 gD1 in a total volume of 100 µl on days 0, 21 and 42 (gD1 group). NLX (Sigma) was dissolved in 100 µl PBS containing 50 µg of the pcDNA3 gD1 construct at a concentration of 5 mg kg–1 and injected to each mouse with the same protocol, i.e. NLX was administered intra-dermally in combination with the pcDNA3 gD1 on days 0, 21 and 42 (NLX-gD1 group). PBS was injected according to the same protocol into the third group of mice as a negative control (PBS group). Finally, the last control group of mice was inoculated according to the same protocol with 100 µl of inoculums containing 10^5 plaque-forming units (pfu) of KOS strain virus (KOS group) (Jamali et al., 2009).
• Challenge Protocol: Three weeks after the last immunization, mice were challenged with a low dose [four mouse lethal dose fifty percent (MLD50) = 1 x 10^5 pfu] or a high dose (10 MLD50 = 1 x 10^5 pfu) of wild-type virus. The mortality rate was followed for 2 weeks (Jamali et al., 2009).
• Efficacy: BALB/c mice receiving a glycoprotein D1 (gD1, US5) DNA vaccine alone were 80% protected against a subsequent HSV-1 challenge. Results also indicate that the administration of NLX as an adjuvant improved protective immunity against HSV-1 (Jamali et al., 2009).